Additional file 1 of Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials
Creators: name: De Filippo, Ovidio
name: D’Ascenzo, Fabrizio
name: Iannaccone, Mario
name: Bertaina, Maurizio
name: Leone, Attilio
name: Borzillo, Irene
name: Ravetti, Emanuele
name: Solano, Andrea
name: Pagliassotto, Ilaria
name: Nebiolo, Marco
name: Bruno, Francesco
name: Giacobbe, Federico
name: Muscoli, Saverio
name: Monticone, Silvia
name: Brizzi, Maria Felice
name: Biondi Zoccai, Giuseppe
name: De Ferrari, Gaetano Maria
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: Additional file 1: Figure S1. PRISMA flowchart for study selection. Table S1. Baseline features of included patients. Figure S2. Risk of Bias assessment of included trials. Figure S3. Peto Odds ratio for stroke, cardiovascular death and all-cause death.. Figure S4. Risk of MACE according to inclusion criteria and background medical history. (excel sheet provided separately). Figure S5. Sensitivity analysis for MACE (excluding trials with arms of BA and ezetimibe). Figure S6. Efficacy of BA compared to control for percentage reduction at 12 weeks of LDL-cholesterol, total cholesterol and non-HDL cholesterol, apolipoprotein B, high-sensitivity C reactive protein (hs-CRP). Figure S7. Efficacy of BA on laboratory endpoints at latest available follow-up: effect of LDL-C, total cholesterol, and non-HDL-C. Figure S8. Efficacy of BA on laboratory endpoints at latest available follow-up: effect on Apo-B and hs-PCR. Figure S9. Sensitivity analysis: efficacy of BA on % reduction of LDL-c after excluding arms of BA + ezetimibe. Figure S10. Efficacy of BA on LDL-C % reduction according to background medical history and trials’ inclusion criteria. Figure S11. Efficacy of BA on total cholesterol and non HDL-cholesterol according to background medical history and trials’ inclusion criteria. Figure S12. efficacy of BA on HS CPR and ApoB lipoprotein according to background medical history and trials’ inclusion criteria. Figure S13. Efficacy of BA on LDL reduction according to statin background therapy. Figure S14. Efficacy of BA on LDL reduction according to background ezetimibe therapy. Figure S15. Risk of any adverse event, serious adverse events and drug discontinuation due to an adverse event. Table S3. Metaregression analysis. Figure S16. Metaregression analysis. Impact of age on the risk of MACE. Figure S17. Metaregression analysis. Impact of male gender on the risk of MACE. Figure S18. Metaregression analysis. Impact of baseline LDL-C on the risk of MACE. Figure S19. Metaregression analysis. Impact of diabetes on the risk of MACE. Figure S20. Metaregression analysis. Impact of age on the difference in reduction of LDL-c between patients receiving bempedoic acid and control treatment group. Figure S21. Metaregression analysis. Impact of male gender on the difference in reduction of LDL-c between patients receiving bempedoic acid and control treatment group. Figure S22. Metaregression analysis. Impact of baseline LDL-c on the difference in reduction of LDL-c between patients receiving bempedoic acid and control treatment group. Figure S23. Metaregression analysis. Impact of diabetes on the difference in reduction of LDL-c between patients receiving bempedoic acid and control treatment group.